Skip to main content
. Author manuscript; available in PMC: 2010 Jul 30.
Published in final edited form as: Clin Cancer Res. 2008 Mar;14(6):1744–1752. doi: 10.1158/1078-0432.CCR-07-1833

Table 2.

Univariate and Multivariate Analysis of 36-gene Signature and Usual Pronostic Factors in Relation to DFS

Predictive Factors Univariate Analysis Multivariate Analysis
Odds Ratio 95% CI P Odds Ratio 95% CI P
A - Training set (132 patients)
36-gene signature: RF v. R 14.61 6.07 to 35.19 6.3 · 10−11 17.89 5.62 to 56.94 1.05 · 10−6
SBR Grade: I/II v. III 4.60 1.87 to 11.27 0.0008 1.46 0.37 to 5.74 0.59
Tumor size: < 20mm v. ≥ 20mm 1.99 0.86 to 4.57 0.11 - - -
PR: ≥ 20 fmol/mg v. <20 fmol/mg 3.68 1.49 to 9.07 0.005 2.73 0.68 to 10.91 0.16
Age: ≥ 55 years v. <55 years 1.87 0.57 to 6.10 0.31 - - -
ER: ≥ 20 fmol/mg v. < 20 fmol/mg 1.07 0.26 to 4.51 0.95 - - -
Node status: pN0 v. pN+ 4.58 2.03 to 10.33 0.0001 3.05 0.75 to 12.45 0.12
NPI: ≤ 3.4 v. > 3.4 7.16 2.33 to 22.04 0.0001 3.27 0.64 to 16.82 0.16
Adjuvant !: < 20% v. ≥ 20% 4.71 2.08 to 10.67 0.0002 1.22 0.31 to 4.76 0.78
B- Validation set (83 patients)
36-gene signature: RF v. R 3.96 1.56 to 10.05 0.004 3.01 1.01 to 9.14 0.05
SBR Grade: I/II v. III 2.02 0.76 to 5.39 0.17 - - -
Tumor size: < 20mm v. ≥ 20mm 2.16 0.83 to 5.60 0.12 - - -
PR: ≥ 20 fmol/mg v. <20 fmol/mg 2.16 0.72 to 6.52 0.18 - - -
Age: ≥ 55 years v. <55 years 2.41 0.62 to 9.30 0.22 - - -
ER: ≥ 20 fmol/mg v. < 20 fmol/mg 4.65 0.46 to 46.69 0.21 - - -
Node status: pN0 v. pN+ 2.37 0.92 to 6.10 0.08 - - -
NPI: ≤ 3.4 v. > 3.4 5.96 1.25 to 28.33 0.013 2.27 0.35 to 14.35 0.38
Adjuvant !: < 20% v. ≥ 20% 4.90 1.75 to 13.69 0.002 2.64 0.78 to 8.91 0.12

DFS, disease-free survival; RF, relapse-free; R, relapse; PR, progesterone receptor; ER, estrogen receptor; NPI, Nottingham prognostic index; v., versus; P, p value. Univariate and multivariate analyses were performed by logistic regression.

Multivariate analysis was performed using the parameters found to be significant in univariate analysis.